253 related articles for article (PubMed ID: 20357749)
1. The efficacy of oral beraprost sodium, a prostaglandin I2 analogue, for treating intermittent claudication in patients with arteriosclerosis obliterans.
Matsumoto T; Iwasa K; Kyuragi R; Honma K; Guntani A; Ohmine T; Itoh H; Onohara T; Maehara Y
Int Angiol; 2010 Apr; 29(2 Suppl):49-54. PubMed ID: 20357749
[TBL] [Abstract][Full Text] [Related]
2. Treatment of intermittent claudication with beraprost sodium, an orally active prostaglandin I2 analogue: a double-blinded, randomized, controlled trial.
Mohler ER; Hiatt WR; Olin JW; Wade M; Jeffs R; Hirsch AT
J Am Coll Cardiol; 2003 May; 41(10):1679-86. PubMed ID: 12767646
[TBL] [Abstract][Full Text] [Related]
3. Effects of beraprost sodium (Dorner) in patients with diabetes mellitus complicated by chronic arterial obstruction.
Toyota T; Oikawa S;
Angiology; 2002; 53(1):7-13. PubMed ID: 11863312
[TBL] [Abstract][Full Text] [Related]
4. Oral Beraprost sodium, a prostaglandin I(2) analogue, for intermittent claudication: a double-blind, randomized, multicenter controlled trial. Beraprost et Claudication Intermittente (BERCI) Research Group.
Lièvre M; Morand S; Besse B; Fiessinger JN; Boissel JP
Circulation; 2000 Jul; 102(4):426-31. PubMed ID: 10908215
[TBL] [Abstract][Full Text] [Related]
5. Conservative treatment for patients with intermittent claudication.
Sugimoto I; Ohta T; Ishibashi H; Iwata H; Yamada T; Tadakoshi M; Hida N; Orimoto Y
Int Angiol; 2010 Apr; 29(2 Suppl):55-60. PubMed ID: 20357750
[TBL] [Abstract][Full Text] [Related]
6. Long-term effects of beraprost sodium on arteriosclerosis obliterans: a single-center retrospective study of Japanese patients.
Arai T
Adv Ther; 2013 May; 30(5):528-40. PubMed ID: 23749750
[TBL] [Abstract][Full Text] [Related]
7. A dose-effect study of beraprost sodium in intermittent claudication.
Lievre M; Azoulay S; Lion L; Morand S; Girre JP; Boissel JP
J Cardiovasc Pharmacol; 1996 Jun; 27(6):788-93. PubMed ID: 8761844
[TBL] [Abstract][Full Text] [Related]
8. Prospective study of sarpogrelate hydrochloride on patients with arteriosclerosis obliterans.
Ren S; Qian S; Wang W; Liu J; Liu P
Ann Thorac Cardiovasc Surg; 2013; 19(1):30-4. PubMed ID: 23364237
[TBL] [Abstract][Full Text] [Related]
9. Restoring vascular nitric oxide formation by L-arginine improves the symptoms of intermittent claudication in patients with peripheral arterial occlusive disease.
Böger RH; Bode-Böger SM; Thiele W; Creutzig A; Alexander K; Frölich JC
J Am Coll Cardiol; 1998 Nov; 32(5):1336-44. PubMed ID: 9809945
[TBL] [Abstract][Full Text] [Related]
10. Successful treatment of intermittent claudication due to spinal canal stenosis using beraprost sodium, a stable prostaglandin I2 analogue. A case report.
Kato H; Emura S; Ngashima K; Kishikawa H; Takashima T; Ohmori K
Angiology; 1997 May; 48(5):457-61. PubMed ID: 9158390
[TBL] [Abstract][Full Text] [Related]
11. Beraprost for the treatment of intermittent claudication.
Cooper LT
J Am Coll Cardiol; 2003 May; 41(10):1687-9. PubMed ID: 12767647
[No Abstract] [Full Text] [Related]
12. Effects of oral beraprost sodium, a prostaglandin I2 analogue, on endothelium dependent vasodilatation in the forearm of patients with coronary artery disease.
Ohata S; Ishibashi Y; Shimada T; Takahashi N; Sugamori T; Sakane T; Hirano Y; Oyake N; Murakami Y; Higami T
Clin Exp Pharmacol Physiol; 2006 Apr; 33(4):381-7. PubMed ID: 16620305
[TBL] [Abstract][Full Text] [Related]
13. Beraprost: a review of its pharmacology and therapeutic efficacy in the treatment of peripheral arterial disease and pulmonary arterial hypertension.
Melian EB; Goa KL
Drugs; 2002; 62(1):107-33. PubMed ID: 11790158
[TBL] [Abstract][Full Text] [Related]
14. The impact of different supervised exercise regimens on endothelial function in patients with intermittent claudication.
Delaney CL; Miller MD; Allan RB; Spark JI
Vascular; 2015 Dec; 23(6):561-9. PubMed ID: 25406267
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic Effects of Medication Use on Intermittent Claudication: A Network Meta-analysis.
Ma B; Fan X; Liu P
J Cardiovasc Pharmacol; 2021 Feb; 77(2):253-262. PubMed ID: 33235027
[TBL] [Abstract][Full Text] [Related]
16. Improving walking ability and ankle brachial pressure indices in symptomatic peripheral vascular disease with intermittent pneumatic foot compression: a prospective controlled study with one-year follow-up.
Delis KT; Nicolaides AN; Wolfe JH; Stansby G
J Vasc Surg; 2000 Apr; 31(4):650-61. PubMed ID: 10753272
[TBL] [Abstract][Full Text] [Related]
17. Beraprost Sodium Protects Against Diabetic Nephropathy in Patients with Arteriosclerosis Obliterans: A Prospective, Randomized, Open-label Study.
Shima A; Miyamoto M; Kubota Y; Takagi G; Shimizu W
J Nippon Med Sch; 2015; 82(2):84-91. PubMed ID: 25959199
[TBL] [Abstract][Full Text] [Related]
18. A randomized trial of iloprost in patients with intermittent claudication.
Creager MA; Pande RL; Hiatt WR
Vasc Med; 2008 Feb; 13(1):5-13. PubMed ID: 18372433
[TBL] [Abstract][Full Text] [Related]
19. Impact of a 4-week treatment with prostaglandin E1 on health-related quality of life of patients with intermittent claudication.
Mangiafico RA; Messina R; Attinà T; Dell'Arte S; Giuliano L; Malatino LS
Angiology; 2000 Jun; 51(6):441-9. PubMed ID: 10870853
[TBL] [Abstract][Full Text] [Related]
20. Studies on the effectiveness and safety of cilostazol, beraprost sodium, prostaglandin E1 for the treatment of intermittent claudication.
Hashiguchi M; Ohno K; Saito R
Yakugaku Zasshi; 2004 Jun; 124(6):321-32. PubMed ID: 15170067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
